Queen's University at Kingston

Treventis Corporation

Bellus Health (international) Limited

Other

National Research Council of Canada

Neurochem (international) Limited

Neurochem, Inc.

Donald F Weaver

Walter A Szarek

Robert Kisilevsky

Richard J Riopelle

Igor L Shamovsky

Gregory M Ross

Xianqi Kong

David Migneault

Ajay Gupta

John R Carran

Sandra Marone

Michael D Carter

Christopher J Barden

Fan Wu

Christopher McMaster

Erhu Lu

Mark A Reed

Shengguo Sun

Arun Yadav

David Byers

Paul Fraser

Magdalena I Dory

Angela P Lyon

Allyson J Campbell

Kathryn Jones

Ryan D'arcy

Buhendwa Musole Guillain

Fuye Gao

Sheila Marie H Jacobo

Sujoy Ghosh Hajra

Careesa Liu

Lauren Sculthorpe-Petley

Fuqiang Ban

Annette Henneberry

Chris Barden

Lauren Sculthorpe

Methods for identifying compounds that are inhibitors or are likely to be inhibitors of amyloid protein aggregation, as well as three-dimensional, non-crystallographic models (i.e. 'pseudo-crystal structures') of amyloid aggregation utilized in the methods, are described. Means for creating the three-dimensional, non-crystallographic models (i.e. 'pseudo-crystal structures') of amyloid aggregation are also described.

Methods for identifying inhibitors of amyloid protein aggregation

A method for analysis of the extent of conscious awareness and likelihood of recovery of a patient includes the steps of applying to the patient a sensory stimulus sequence which is typically auditory; carrying out an EEG to generate waveform signals to record changes in the electromagnetic fields generated by the patient's neural activity; using software provided in a processor to process the waveform signals in order to locate waveform peaks, identify the event-related potential (ERP) components obtained in the waveform and to obtain quantitative measures of those components; and using the software to generate and communicate scores indicative of the extent of conscious awareness and likelihood of recovery of the patient.

Cognitive function assessment in a patient

The synthesis and activity of novel LpxA inhibitors is described, these inhibitors present antibacterial activity. The compounds were designed based on a receptor model developed using the crystal structure of LpxA and are arranged to have a favorable binding interaction at the active site of the enzyme. In particular, the compounds present the following formula (I) where V, W, X, Y and Z can be independently C, S, N or O and P1, P2 and P3 are ligands to bind to the three points of the proposed pharmacophore model. They can be chosen from a variety of groups.

Synthesis of novel antimicrobials

The present invention is directed to compounds that inhibit amyloid aggregation and methods of treatment therewith.

Methods of treating amyloid disease using analogs of 1-(4-nitrophenyl) piperazine

The invention is directed to compounds and methods for treating protein folder disorders. In certain embodiments the invention provides compounds and methods for treating neurodegenerative diseases such as Alzheimer's disease, tauopathy, cerebral amyloid angiopathy, Lewy body disease, dementia, Huntington's disease and prion-based spongiform encelopathy. The invention further provides compounds, methods and pharmaceutical compositions for inhibiting tau protein, A&#x3b2; protein or &#x3b1;-synuclein protein aggregation.

Compounds and methods for treating protein folding disorders

Methods and compositions which are useful in the treatment of amyloidosis. In particular, methods and compositions are provided for inhibiting, preventing and treating amyloid deposition, e.g., in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. The methods of the invention involve administering to a subject a therapeutic compound which inhibits IAPP-associated amyloid deposits. Accordingly, the compositions and methods of the invention are useful for inhibiting IAPP-associated amyloidosis in disorders in which such amyloid deposition occurs, such as diabetes.

Methods and compounds for inhibiting amyloid deposits

Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.

Sulfonated compounds and compositions for treating amyloidosis

Methods and compounds useful for the inhibition of convulsive disorders, including epilepsy, are disclosed. The methods and compounds of the invention inhibit or prevent ictogenesis and/or epileptogenesis. Methods for preparing the compounds of the invention are also described. Particularly preferred compounds of the invention include: 

Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents

The present invention exploits the discovery that amounts of uracil and thymine metabolites, especially &#x3b2;-aminoisobutyric acid, in various bodily fluids, especially urine, are correlated with the occurrence of epilepsy when compared to matched control subjects. Analytical and diagnostic protocols, including a novel high performance liquid chromatography system, for use in the invention are disclosed.

Diagnostic methods for determining susceptibility to convulsive conditions

The present invention relates to compositions which inhibit the binding of nerve growth factor to the p75common neurotrophin receptor and methods of use thereof. In one embodiment, the compound which inhibits binding of nerve growth factor to p75comprises, particularly when bound to nerve growth factor, at least two of the following: (1) a first electronegative atom or functional group positioned to interact with Lysof nerve growth factor; (2) a second electronegative atom or functional group positioned to interact with Lysof nerve growth factor; (3) a third electronegative atom or functional group positioned to interact with Lysof nerve growth factor; (4) a fourth electronegative atom or functional group positioned to interact with Lysof nerve growth factor; and (5) a hydrophobic moiety which interacts with the hydrophobic region formed by Ile, Pheand Pheof nerve growth factor.

Method of inhibiting neurotrophin-receptor binding

Methods and compounds useful for the inhibition of convulsive disorders, including epilepsy, are disclosed. The methods and compounds of the invention inhibit or prevent ictogenesis and epileptogenesis. Methods for preparing the compounds of the invention are also described.

Anti-epileptogenic agents

The present invention relates to compositions which inhibit the binding of nerve growth factor to the p75 common neurotrophin receptor and methods of use thereof. In one embodiment, the compound which inhibits binding of nerve growth factor to p75 comprises, particularly when bound to nerve growth factor, at least two of the following: (1) a first electronegative atom or functional group positioned to interact with Lys of nerve growth factor; (2) a second electronegative atom or functional group positioned to interact with Lys of nerve growth factor; (3) a third electronegative atom or functional group positioned to interact with Lys of nerve growth factor; (4) a fourth electronegative atom or functional group positioned to interact with Lys of nerve growth factor; and (5) a hydrophobic moiety which interacts with the hydrophobic region formed by Ile , Phe and Phe of nerve growth factor.

Method of inhibiting binding of nerve growth factor to p75 NTR receptor

Growing community of inventors

Halifax, Canada

Donald F Weaver